These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22214461)

  • 1. Inflammation and antiangiogenesis in cancer.
    Ribatti D; Crivellato E; Vacca A
    Curr Med Chem; 2012; 19(7):955-60. PubMed ID: 22214461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy.
    Tartour E; Pere H; Maillere B; Terme M; Merillon N; Taieb J; Sandoval F; Quintin-Colonna F; Lacerda K; Karadimou A; Badoual C; Tedgui A; Fridman WH; Oudard S
    Cancer Metastasis Rev; 2011 Mar; 30(1):83-95. PubMed ID: 21249423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-27 in tumor immunity and immunotherapy.
    Murugaiyan G; Saha B
    Trends Mol Med; 2013 Feb; 19(2):108-16. PubMed ID: 23306374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innate immune mediators in cancer: between defense and resistance.
    Berraondo P; Minute L; Ajona D; Corrales L; Melero I; Pio R
    Immunol Rev; 2016 Nov; 274(1):290-306. PubMed ID: 27782320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dormant tumors and organs resistant to metastasis after gene transfer: dream and reality of anti-angiogenic gene therapy].
    Li H; Dkhissi F; Grenet C; Soria C; Lu H
    Therapie; 2001; 56(5):501-10. PubMed ID: 11806286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mast cells as effector cells of innate immunity and regulators of adaptive immunity.
    Cardamone C; Parente R; Feo GD; Triggiani M
    Immunol Lett; 2016 Oct; 178():10-4. PubMed ID: 27393494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New perspectives on type I IFNs in cancer.
    Gajewski TF; Corrales L
    Cytokine Growth Factor Rev; 2015 Apr; 26(2):175-8. PubMed ID: 25630967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune cells and angiogenesis.
    Ribatti D; Crivellato E
    J Cell Mol Med; 2009 Sep; 13(9A):2822-33. PubMed ID: 19538473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor.
    Santoni M; Berardi R; Amantini C; Burattini L; Santini D; Santoni G; Cascinu S
    Int J Cancer; 2014 Jun; 134(12):2772-7. PubMed ID: 24114790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer immunotherapy of targeting angiogenesis.
    Hou J; Tian L; Wei Y
    Cell Mol Immunol; 2004 Jun; 1(3):161-6. PubMed ID: 16219162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour-induced immune suppression: role of inflammatory mediators released by myelomonocytic cells.
    Mao Y; Poschke I; Kiessling R
    J Intern Med; 2014 Aug; 276(2):154-70. PubMed ID: 24597954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross talk between natural killer cells and mast cells in tumor angiogenesis.
    Ribatti D; Tamma R; Crivellato E
    Inflamm Res; 2019 Jan; 68(1):19-23. PubMed ID: 30132016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming the hurdles of tumor immunity by targeting regulatory pathways in innate and adaptive immune cells.
    Zwirner NW; Croci DO; Domaica CI; Rabinovich GA
    Curr Pharm Des; 2010 Jan; 16(3):255-67. PubMed ID: 20109135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics.
    Hegde PS; Wallin JJ; Mancao C
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):117-124. PubMed ID: 29229461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Innate-Adaptive Immune Crosstalk.
    Shanker A; Thounaojam MC; Mishra MK; Dikov MM; Uzhachenko RV
    J Immunol Res; 2015; 2015():982465. PubMed ID: 26618182
    [No Abstract]   [Full Text] [Related]  

  • 16. Control of cancers by combining antiangiogenesis and cancer immunotherapy.
    Moniz M; Yeatermeyer J; Wu TC
    Drugs Today (Barc); 2005 Jul; 41(7):471-94. PubMed ID: 16193100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination approach to anti-angiogenic treatment of cancer.
    Wentink MQ; Huijbers EJ; de Gruijl TD; Verheul HM; Olsson AK; Griffioen AW
    Biochim Biophys Acta; 2015 Apr; 1855(2):155-71. PubMed ID: 25641676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impacts of cigarette smoking on immune responsiveness: Up and down or upside down?
    Qiu F; Liang CL; Liu H; Zeng YQ; Hou S; Huang S; Lai X; Dai Z
    Oncotarget; 2017 Jan; 8(1):268-284. PubMed ID: 27902485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiangiogenesis: the fifth cancer treatment modality?
    Camp-Sorrell D
    Oncol Nurs Forum; 2003; 30(6):934-44. PubMed ID: 14603351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine networking of innate immunity cells: a potential target of therapy.
    Striz I; Brabcova E; Kolesar L; Sekerkova A
    Clin Sci (Lond); 2014 May; 126(9):593-612. PubMed ID: 24450743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.